Phathom Pharmaceuticals, Inc.

PHAT Nasdaq SEC CIK 1783183
Follow Phathom Pharmaceuticals Weekly email: filings, results

Financials

Reported figures only · latest: Q3 2026 USD · US GAAP
Revenue, last quarter $84.7M +71.1% vs same quarter last year
Net income −$13.9M +53.6% vs same quarter last year
EPS, diluted −$0.16 +61% vs same quarter last year
Operating cash flow $1.8M +113% vs same quarter last year
Revenue by quarter
$29.7M
$28.5M
$39.5M
$49.5M
$57.6M
$58.3M
$74.3M
$84.7M
Q4 24 Q1 25 Q2 25 Q3 25 Q4 25 Q1 26 Q2 26 Q3 26

Source: SEC XBRL filings · latest filing

The long view

Fiscal years as reported · SEC XBRL filings, US GAAP
Revenue and net income9 fiscal years
  • Revenue
  • Net income
−$400M−$200M$0$200MFY17FY18FY19FY20FY21FY22FY23FY24FY25
Show the numbers
YearRevenueNet income
FY25$175.1M−$221.3K
FY24$55.3M−$334.3K
FY23$682K−$201.6K
FY22$0−$197.7M
FY21-−$143.9M
FY20-−$129.1M
FY19-−$255.1M
FY18-−$1.3M
FY17--
MarginsShare of revenue
  • Gross margin
  • Operating margin
  • Net margin
−30000%−20000%−10000%0%10000%FY17FY18FY19FY20FY21FY22FY23FY24FY25
Show the numbers
YearGross marginOperating marginNet margin
FY2587.1%−91.4%−0.1%
FY2485.6%−502.2%−0.6%
FY2375.5%−24532.6%−29.6%
FY22---
FY21---
FY20---
FY19---
FY18---
FY17---
Free cash flowOperating cash flow minus capital expenditure
−$300M−$200M−$100M$0FY17FY18FY19FY20FY21FY22FY23FY24FY25
Show the numbers
YearFree cash flow
FY25−$167M
FY24−$266.9M
FY23−$139.2M
FY22−$147.6M
FY21−$148.8M
FY20−$70.7M
FY19−$36.6M
FY18-
FY17-
Net margin vs the sectorMedian of Healthcare companies filing with the SEC
  • Phathom Pharmaceuticals
  • Healthcare median
−100%−75%−50%−25%0%FY17FY18FY19FY20FY21FY22FY23FY24FY25
Show the numbers
YearPhathom PharmaceuticalsHealthcare median
FY25−0.1%−30.6%
FY24−0.6%−47%
FY23−29.6%−58%
FY22-−80.4%
FY21-−71.8%
FY20-−62.2%
FY19-−46.2%
FY18-−49.6%
FY17-−45.9%